- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00548652
Role of Apathy in the Effectiveness of Weight Loss Interventions
Role of Apathy in the Effectiveness of Weight Loss Interventions in Obese Patients
연구 개요
상세 설명
Title: The role of Apathy in the effectiveness of weight loss interventions in obese patients
Objective: Obesity is a major public health problem. Apathy is a common behavioral problem characterized by loss of initiative, poor motivation and persistence. Presence of apathy impairs the self-care behavior in obese patients. Lack of novelty might impair a patient's ability to seek new interactions, life styles and new treatment options for obesity. Lack of motivation might impair a patient's ability to initiate exercise regimen or diet whereas lack of persistence impairs the compliance with these regimens. Thus, apathy influences all stages of self-care. We hypothesize that the treatment of apathy will result in better adherence to weight loss interventions in obese veterans enrolled in the MOVE program.
Research Design: A prospective open label randomized study. Group 1 will have patients with obesity as defined as BMI>30, and apathy defined as AES score of > 40. This group will be treated with standard nutrition counseling. Group 2 will have patients with obesity and apathy as defined above and will receive the MOVE enhancement program alone (The MOVE program is a national VA weight loss program). Group 3 will be treated with methylphenidate along with the MOVE enhancement program. Group 4 will be treated with medical crisis counseling along with the MOVE enhancement program. Group 5 will be treated with methylphenidate, and the medical crisis counseling along with the MOVE enhancement program.
Methodology: 30 patients meeting the criteria will be enrolled in each of the five arms. All patients will be in the study for duration of six months. All patients in the methylphenidate arm will be started at 5mg twice daily and titrated to 10mg twice daily at two weeks. Patients will be assessed on regular intervals using the Apathy Evaluation Scale, Hamilton Depression Scale and the Patient activation measure. MOVE sessions will be held once weekly from the 2nd visit to the end of the study. Medical Crisis Counseling visits will be every week for nine sessions and then every other week till the end of the study
Clinical Relationships/Significance: The prevalence of obesity in the general population is over 30%. However the prevalence of obesity in the VA health system is almost 70%. Since obesity predisposes to several co-morbid conditions such as hypertension, diabetes and cardiovascular disease, it is important to develop interventions that are effective in inducing weight loss. Since apathy plays a large role in the self care behaviours that lead to obesity, treating apathy may improve adherence to weight loss programs
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68105-1873
- VA Medical Center, Omaha
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- BMI >30
- Apathy score >40
Exclusion Criteria:
- History of cancer, except basal cell
- Cardiovascular event in last 6 months
- Renal failure
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: 1
standard nutrition counselling
|
|
|
실험적: 2
MOVE -weight loss intervention
|
is a VA based multidesciplinary weight loss intervention
|
|
실험적: 3
MOVE plus medical crisis counselling
|
is a VA based multidesciplinary weight loss intervention
group counselling sessions
|
|
실험적: 4
MOVE plus methylphenidate
|
is a VA based multidesciplinary weight loss intervention
methyphenidate will be used to treat apathy dose 10mg bid
|
|
실험적: 5
MOVE plus methyphenidate plus medical crisis counselling
|
is a VA based multidesciplinary weight loss intervention
group counselling sessions
methyphenidate will be used to treat apathy dose 10mg bid
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Apathy Evaluation Scale
기간: 6 months
|
Apathy Evaluation Scale (AES) measures apathy over the previous four weeks Scale range: 18 (minimum score)- 72 (Maximum score) Higher scores indicate higher apathy Better outcome would be reduction in the score
|
6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Weight
기간: 6 months
|
value at 6 months minus value at baseline
|
6 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Cyrus DeSouza, MD, VA Medical Center, Omaha
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
MOVE에 대한 임상 시험
-
VA Office of Research and Development완전한
-
MMSx Authority Institute for Movement Mechanics...완전한
-
VA Puget Sound Health Care System완전한
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); University of Rochester; University of Massachusetts, Boston완전한
-
Barron Associates, Inc.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Duke University 그리고 다른 협력자들완전한
-
Charles University, Czech Republic모집하지 않고 적극적으로
-
Northwestern UniversityLynn Sage Breast Cancer Research Foundation완전한유방암 여성
-
NGMedical GmbH모병